Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | TYK2 | P29597 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL18453954 | 1.00 | JAK2 (0.48) | JAK2TYK2JAK1JAK3L3MBTL1 | |
| SCHEMBL29544286 | 0.89 | POLB (0.47) | JAK2TYK2JAK1JAK3L3MBTL1 | |
| SCHEMBL28717895 | 0.89 | POLB (0.47) | JAK2TYK2JAK1JAK3L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL29544489 | 0.88 | DEGS1 (0.43) | EP300DEGS1POLBRAB9AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL28708393 | 0.88 | DEGS1 (0.43) | EP300DEGS1POLBRAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL4249740 | 0.88 | DGAT1 (0.46) | JAK2TYK2JAK1JAK3L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL18453319 | 0.86 | AOC3 (0.44) | CDK4CCNA2CDK2CCND3CDK6 | |
| Trifluoroacetic Acid SCHEMBL29544383 | 0.86 | AOC3 (0.44) | CDK4CCNA2CDK2CCND3CDK6 | |
| Trifluoroacetic Acid SCHEMBL18453160 | 0.86 | CDK6 (0.46) | CDK4CCNA2CDK2CCND3CDK6 | |
| Trifluoroacetic Acid SCHEMBL28705254 | 0.86 | AOC3 (0.44) | CDK4CCNA2CDK2CCND3CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Thereapeutics Pty LTD (AU) | 2025-02-20 | — | — | US | disclosed |
| US-20250049796-A1 | USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-02-13 | — | — | US | disclosed |
| EP-4504200-A1 | USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER | Aucentra Therapeutics Pty Ltd (AU) | 2025-02-12 | — | — | EP | disclosed |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-04-30 | — | — | US | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| WO-2023173170-A1 | USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-09-21 | — | — | WO | disclosed |
| EP-3957637-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-06-28 | — | — | EP | disclosed |
| US-20230181580-A1 | TREATMENT OF PROLIFERATIVE DISEASES OF THE CNS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-06-15 | — | — | US | disclosed |
| EP-4146201-A1 | TREATMENT OF PROLIFERATIVE DISEASES OF THE CNS | Aucentra Therapeutics Pty Ltd (AU) | 2023-03-15 | — | — | EP | disclosed |
| CN-115666561-A | Treatment of proliferative diseases of the CNS | 澳升医药公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-3957637-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Therapeutics Pty Ltd (AU) | 2022-02-23 | — | — | EP | disclosed |
| EP-3331880-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021222967-A1 | TREATMENT OF PROLIFERATIVE DISEASES OF THE CNS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-11-11 | — | — | WO | disclosed |
| CN-113336746-A | N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds | 常州千红生化制药股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-108349964-B | N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds | 常州千红生化制药股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2019-11-19 | — | — | US | disclosed |
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2018-08-09 | — | — | US | disclosed |
| EP-3331880-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | University Of South Australia (AU) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017020065-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | UNIVERSITY OF SOUTH AUSTRALIA (AU) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181580-A1 | TREATMENT OF PROLIFERATIVE DISEASES OF THE CNS | CDK6, CDK4, CDK3 | JAK2 78/4885TYK2 715/4885JAK1 92/4885 |
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | JAK2 73/4885TYK2 163/4885JAK1 66/4885 |
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | JAK2 73/4885TYK2 171/4885JAK1 64/4885 |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | CDK4, CDK6, CDK2 | JAK2 73/4885TYK2 163/4885JAK1 66/4885 |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDKL2 | JAK2 77/4885TYK2 168/4885JAK1 70/4885 |
| US-20250049796-A1 | USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER | CD274, PDCD1LG2, PDCD1 | JAK2 150/4885TYK2 136/4885JAK1 149/4885 |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | CDK4, CDK6, CDK3 | JAK2 106/4885TYK2 247/4885JAK1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.